ZEB2 overexpression plays a clear oncogenic role in early T-cell precursor leukemia (ETP-ALL) [28, 29]; therefore, direct application of T-bet or Zeb2 gain-of-function in CD8+ cells will likely be of little clinical utility. This evidence concerns the gene TBX21 and acute lymphoblastic leukemia.